GERON CORP
No enriched coverage for $GERN in the last 7 days.
No SEC Form 4 filings for $GERN in the last 30 days.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Geron ( GERN ) To Contact Him Directly To Discuss Their Options
FOSTER CITY, Calif., Oct. 13, 2025 ( GLOBE NEWSWIRE ) -- Geron Corporation ( NASDAQ:GERN ) , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transitions and appointments designed to align the company's ...
Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations ...
